A groundbreaking gene therapy designed to treat cystic fibrosis shows remarkable staying power—a single dose delivered to primates produced sustained benefits, regardless of which CF mutation patients carry.

This development represents a significant leap forward in CF treatment because most therapies currently target only specific mutations. The ability to use one-size-fits-most approach could dramatically simplify care for the roughly 30,000 people living with cystic fibrosis in the US alone. The inhaled delivery method also means patients won't need invasive procedures. Read the full story →

Today's takeaway: This breakthrough could transform CF from a lifelong treatment burden into a potentially one-time intervention.